SDS-19CAR / Innovative Cellular Therapeutics - LARVOL DELTA

LONG-TERM FOLLOW-UP OF CAR-T THERAPY FOLLOWED BY HAPLOIDENTICAL HSCT FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER RETROSPECTIVE STUDY (EBMT 2025) - P=N/A | " We previously reported the results of 122 patients with r/r ALL received anti-CD19 CAR-T including 67 patients without subsequent transplantation (non-transplant group) and 55 patients with subsequent haplo-HSCT (transplant group) at a median follow-up of 20.4 months. Haploidentical hematopoietic stem cell transplantation with pre-transplant MRD negativity after CAR-T therapy could greatly improve LFS and OS in patients with relapsed/refractory acute lymphoblastic leukemia. However, infections are key survivorship issues that reduce long-term survival after CAR T-cell therapy. Clinical Trial Registry: The study was registered in the Chinese clinical trial registry (ChiCTR1900023957)."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • Congestive Heart Failure • Graft versus Host Disease • Heart Failure • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial. (PubMed, JAMA Oncol) - "Given the paucity of effective therapeutics developed for colorectal cancer in recent decades, the observation that CD-19 CART target engagement can robustly induce GCC19CART target engagement sufficient to produce objective activity may serve as a foundation to develop effective cellular therapy in mCRC and other solid cancers. Chinese Clinical Trial Registry: ChiCTR2000040645."

CAR T-Cell Therapy • Clinical • Journal • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

A phase 1 dose escalation study of GCC19CART – A novel CoupledCAR® therapy for subjects with metastatic colorectal cancer (SITC 2023) - "CoupledCAR utilizes multiple vectors to make both solid tumor targeting CAR-T and CD19 CAR-T in a single manufacturing step...Eligible subjects undergo leukapheresis, a single dose of lymphodepleting chemotherapy (fludarabine 30mg/m2 and cyclophosphamide 300mg/m2) 3 days prior to infusion, and then administration of a single infusion of GCC19CART at one of two preassigned doses: 1x106 or 2x106 CAR T-cells/kg...This trial is ongoing and updated data will be presented. A Phase 1 trial of GCC19CART in the US has opened for accrual and is expected to enroll patients in mid-2022."

Clinical • IO biomarker • Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer (ESMO 2023) - "CoupledCAR utilizes multiple vectors to make both solid tumor targeting CAR-T and CD19 CAR-T in a single manufacturing step...Eligible subjects undergo leukapheresis, a single dose of lymphodepleting chemotherapy (fludarabine 30mg/m2 and cyclophosphamide 300mg/m2) 3 days prior to infusion, and then administration of a single infusion of GCC19CART at one of two preassigned doses: Dose 1 (1x106) or Dose 2 (2x106) CAR T-cells/kg...This trial is ongoing and updated data will be presented. A phase 1 trial of GCC19CART in the US has opened for accrual and is expected to enroll patients in mid-2022."

Clinical • Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Novel CoupledCAR technology for treating colorectal cancer (ESMO 2022) - "CoupledCAR utilizes multiple vectors to make both solid tumor targeting CAR-T and CD19 CAR-T in a single manufacturing step...Eligible subjects undergo leukapheresis, a single dose of lymphodepleting chemotherapy (fludarabine 30mg/m 2 and cyclophosphamide 300mg/m 2 ) 3 days prior to infusion, and then administration of a single infusion of GCC19CART at one of two preassigned doses: Dose 1 (1x10 6 ) or Dose 2 (2x10 6 ) CAR T-cells/kg...It was well tolerated and toxicity was manageable. A United States based phase I trial of GCC19CART is anticipated to begin enrolling subjects in mid-2022."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD19

Antigen-independent expansion enhances efficacy of CAR-T cells against solid tumor (AACR 2022) - "Here, we report the characterization of prostatic acid phosphatase (PAP) as a feasible CAR-T target for prostate cancer and a novel approach, named CoupledCAR, to expand solid tumor-targeting CAR-T cells lacking solid tumor antigens based on the observation of non-transduced T cells proliferating together with CD19 CAR-T cells during the treatment of acute lymphocyte leukemia...Furthermore, we showed that the expansion of solid tumor-targeting CAR-T cells does not depend on CAR/CD3ζ stimulation through direct antigen binding with CAR but enhances the memory status of CAR-T cells and causes little exhaustion. Since the CoupledCAR system does not rely on solid tumor antigens, we propose that it can be utilized in all CAR-T and T cell therapies for the treatment of solid tumors."

CAR T-Cell Therapy • Clinical • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Prostate Cancer • Solid Tumor • ACPP • CD19 • PSAP

Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial. (ASCO 2017) - "The anti-IL6R agent tocilizumab and Methylprednisolone were effective confrontation Severe CRS. This is the first multicentre report to our knowledge of successful treatment of r/r ALL with anti-CD19 CAR T cells in China. Even r/r B-ALL with high-burden leukemia patients also was effective and associated with a high remission rate after infused autologous CD19 CAR-T).(NCT 02813837)."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • Biosimilar

Innovative Cellular Therapeutics announces data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) - "ICT’s lead candidate, ICTCAR014, consists of anti-CD19 CAR-T cells with a dominant negative PD1 molecule. Preclinically, these 'armored' CAR-T cells show enhanced capability of tumor killing after multiple-round tumor challenging and more 'memory-like' phenotypes compared with conventional CAR-T cells...In an investigator-sponsored trial in China, two patients treated with ICTCAR014 for refractory diffuse large B-cell lymphoma (DLBCL) demonstrated significant tumor mass decrease as shown in PET/CT results and ongoing responses."

Clinical data • Preclinical